Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Psoriasis
•
Dermatology
Do you caution against starting biologics for psoriasis if patient has hepatitis A antibodies?
Answer from: at Academic Institution
No
Comments
at Jefferson Regional Medical Center
No
12435
Sign in or Register to read more
23143
Related Questions
How does the location or type of psoriasis affect your initial biologic choice?
How do you counsel patients on the risks and benefits of an IL-23 agent versus an IL-17A or IL-17A/F agent?
Are there certain disease domains in a patient with psoriatic arthritis that will make bimekizumab a particularly good option?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
How do you approach management of patients with psoriatic arthritis who have significant improvement in skin disease, but ongoing inflammatory arthritis despite multiple DMARDs and/or biologics?
Do you wait on initiating biologic therapy for guttate psoriasis?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Do you discontinue IL-17A, IL-17A/F, or IL-23 blockade in pregnant patients with psoriasis?
How frequently or soon have you noticed TNF-a induced psoriasiform dermatitis develop?
Are you comfortable utilizing Stelara (ustekinumab) as biologic treatment of psoriasis for patients with a history of severe latex allergy?
No